Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Another asset added to their all star team.
This is great!!! Let's see a big move today.
Tight spread for $GTBP more volume coming in
GT Biopharma’s pipeline of therapies have attracted several industry heavyweights that hail from companies like Pfizer (PFE), Chase Pharmaceuticals, Sanofi (SNY), and Deutsche Bank (DB).
GT Biopharma future plans:
1) GT Biopharma is currently developing several different treatments aimed to treat solid tumors, a specific autoimmune disease, and motion sickness.
2) The bio-pharmaceutical company has seen some signs of success in preliminary trials.
3) GT does not currently generate revenue. This means that they will have to continue to issue shares and seek investors that will continue to fund their projects.
4) GT will need a few hundred million dollars over the next few years in order to continue to fund the R&D on their products.
5) If GT achieves success, their products/company could be an attractive buy for large pharmaceutical companies.
Agreed!Consider What GT Biopharma Could Be In The Future
https://seekingalpha.com/article/4165690-consider-gt-biopharma-future
This is a remarkable time for the development of $GTBP
Seasoned Financial Executive Federica O'Brien Joins GT Biopharma's $GTBP Board of Directors http://marijuanastocks.com/seasoned-financial-executive-federica-obrien-joins-gt-biopharmas-gtbp-board-of-directors/ …
Good morning NYC!!!!
$PAOG Lots of potential to be an awesome money maker!
Multiple clinics opening to help fight the opioid crisis. And yes, cannabis will be included in the realm of treatment solutions.
https://altmedcenters.com/locations-florida/
https://altmedcenters.com/locations-ohio/
Great article! Thanks for sharing
Marijuana is one of the quintessential plants of earth with healing powers that are beyond comprehension, and has been bastardized and criminalized by the governments and corporations that suppress them.
I think the business model of mj clinics to fight opioid addiction is fantastic.
IMO $PAOG management to continue communication clinics update with shareholders and this will continue it's rise above copper. Just a matter of time. Tick tock.
The bigger the problem; the bigger the opportunity for entrepreneurs in fixing the problem ... $PAOG
Whitehouse: One Year of the Opioid Epidemic Cost the US Economy More Than $500 BILLION ...
* https://www.reuters.com/article/legal-us-usa-opioids-cost/opioid-crisis-cost-u-s-economy-504-billion-in-2015-white-house-idUSKBN1DL2Q0
* https://www.vox.com/science-and-health/2017/11/20/16679688/white-house-opioid-epidemic-cost
* https://www.marketwatch.com/story/how-much-the-opioid-epidemic-costs-the-us-2017-10-27
* https://www.cnbc.com/2017/11/20/the-true-cost-of-opioid-epidemic-tops-500-billion-white-house-says.html
Good news for the Cannabis industry as a whole
Nasdaq to Get First Pot Listing
https://www.bloomberg.com/news/articles/2018-02-26/nasdaq-to-get-first-pot-listing-as-cronos-group-joins-exchange?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo
Churning nicely here. Getting ready for the power hour
PAOG chart is looking ripe for a nice run-
"big sissy" is leading the way. all we need is volume, and we're off to the races again.
GO PAOG $$$$$$$$$
Investors in the legal cannabis industry in North America have injected $ 1.23 billion in cannabis companies in a month. In comparison, it is almost 600 percent more than the 178 million in January of last year. The threatening language of the federal government in the US does not make any impression.
Investment register in January
That the fast growth of the legal cannabis industry in North America is more than good, we know it for a long time, but that goes so well ... According to the Viridian Cannabis Deal Tracker , in the first month of 2018 there are 1,230 million dollars registered for new investments, an absolute record.
Not only is that unimaginable amount of 600% more than in the first five weeks of 2017, it even approximates the total amount of last year, of the whole year 2017, when after 12 months finally, 1,290 million dollars were invested in the Cannabis industry of North America.
The money is mainly directed to cannabis growers.
"We see a steady maturation of capital markets around the cannabis industry," said Vice President Harrison Phillips of Viridian Capital Advisors at the Benzinga.com business website. "At first, they were almost exclusively people with a lot of money, and maybe some family businesses, who invested in cannabis. Now we see more and more family businesses, more 'high net worth people' and more professional investors who get involved '.
The cannabis industry is strengthening economically in the North American markets while the rest of the countries act as mere spectators.
http://www.lamarihuana.com/la-industria-del-cannabis-norteamerica-recauda-1-200-millones-enero/
True!!! haha...Fellowship of the pots! LOL
Yes $RSII & $PAOG are Sister Stocks since both stocks were reverse merged well into 2017 and both companies have the same ownership and BOD
https://www.theglobeandmail.com/investing/markets/stocks/RSII/pressreleases/4630103/
Rising Biosciences, Inc. Launches TSW! Topicals (This (Bleep) Works!), Delivering Innovative Pain Relief to Market in Q4; Unveils Scar Peptide Serum
Marketwired - Fri Sep 29, 7:30AM CDT
NEW YORK, NY--(Marketwired - Sep 29, 2017) - Rising India's (OTC:RSII) Rising Biosciences, Inc., a research and development company focusing on oral and topical pharmaceuticals with strict standards set forward by the pharmaceutical compounding industry, announces today that it has launched TSW Topicals (www.TSW-topicals.com), a range of over-the-counter, topical pain relief products using an innovative blend of clinically proven organic ingredients such as menthol, curcumin, ginger and capsaicin to reduce inflammation and effectively relieve pain.
Products include solutions for muscle and joint pain, back pain, neuropathy/nerve pain and arthritis. TSW Pain, a topical pain relief cream for muscle and joint relief, is currently under testing to meet FDA requirements and Rising execs are confident it will hit the market sometime during Q4.
The Company also announces today a trial run of its Clinical Strength Peptide Serum for scar and skin repair. The serum produces visible results with an effective ingredient base and delivery system and Rising BioSciences is launching a sample run for a limited number of subscribers to our newsletter. All you have to do to reserve your sample is visit www.RisingBiosciences.com, scroll to the bottom of the home page and 'Subscribe' to our newsletter while supplies last.
"We have received an overwhelmingly positive response to its trial run for TSW Pain and expect similar feedback for our clinical strength peptide serum," states Doug Bowes, Director of Brand Development.
As well, CEO Robert Weber has been working toward an official name and ticker change for Rising India, Inc. and has retained the services of the same attorney that assisted in successfully attaining the name and symbol change for sister company, PAO Group, Inc. (OTC:PAOG)
$RSII on Twitter for LIVE company updates! www.twitter.com/risingindiausa
Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward- looking statements to reflect events or circumstances after the date of this release.
Nice volume today. The run is coming. Tick tock.
Israel Scientific Study: Cannabis Safe and Effective for Regular Use in the Elderly; Can Decrease the Use of Other Prescription Medicines, Including Opioids
First-of-its-Kind, Peer-Reviewed Study of Thousands of Elderly Cannabis Patients under the Care of Tikun Olamâ„¢
NEWS PROVIDED BY
Tikun Olam
07:30 ET
SHARE THIS ARTICLE
NEW YORK, and TEL AVIV, Israel, Feb. 20, 2018 /PRNewswire/ -- A new published clinical study out of Israel offers scientific evidence that the therapeutic use of cannabis can be a safe and effective treatment for elderly people, and is often a factor leading to the decreased use of other drugs, including opioids.
The groundbreaking article, "Epidemiological characteristics, safety and efficacy of medical cannabis in the elderly" published on February 7, 2018 in the European Journal of Internal Medicine, is the first of its kind. The study surveyed patients above 65 years of age who received medical cannabis at Tikun Olam clinics in Israel from January 2015 to October 2017. All 2,736 patients, with a median age of 74.5 years, were prescribed one or more of Tikun Olam's proprietary cannabis strains, each developed over a number of years to address specific symptoms. The main strains used in the study were Erez, (53.2%), Avidekel (33.4%), Alaska (25.7%), and Midnight (20.4%).
The most common indications for cannabis treatment were pain (66.6%) and cancer 60.8%). After six months of treatment, 93.7% of the respondents reported improvement in their condition and the reported pain level was reduced by half -- from a median of 8 on a scale of 0–10 to a median of 4. Adverse side effects were minor and rare and included dizziness (9.7%) and dry mouth (7.1%).
Importantly, after six months, 18.1% of the patients reduced their dose of opioid analgesics -- or stopped using them entirely.
The largest supplier of medical cannabis in Israel, Tikun Olam partnered with Israel's Soroka University Medical Center, Ben-Gurion University of the Negev, and the Hebrew University of Jerusalem for the study. Bernie Sucher, Chief Executive Officer of Tikun Olam Global LLC, said, "This study is an unprecedented affirmation by the scientific community of the efficacy of medical marijuana in the elderly. These people are arguably the most medically vulnerable population and already a large and growing proportion of the users of medical cannabis."
"This pioneering clinical study on the use of cannabis in the geriatric population is the first step in finding safer, and less toxic medications for use in our elderly populations," Sucher added. "We are proud to have partnered with the scientific and academic communities for this release, and ongoing analysis and study will be a significant factor in improving and developing new cannabis products in both the traditional and the pharmaceutical markets."
Full article is available; please contact Tikun Olam Media Relations (listed below) to receive a copy or for more information.
About Tikun Olam
Tikun Olam ("repair the world" in Hebrew) is the world's leading cannabis brand and globally recognized as the pioneer of modern medical cannabis. The company's global mission is to research, develop and provide efficacious, data-based cannabis treatments to help sufferers. Operating as a commercial venture for over 10 years, Tikun Olam's products have been used since 2010 in ongoing clinical trials in Israel's regulated medical cannabis market, treating over 10,000 patients for a variety of symptoms of medical conditions such as Cancer, PTSD, AIDS, epilepsy, Crohn's Disease/Colitis, multiple sclerosis, cerebral palsy, chronic pain and neuropathy. Through this access to patients, medical personnel and data collection, Tikun Olam has developed multiple proprietary strains, including the first-ever, high-CBD, "high-less" strain Avidekelâ„¢, its high-THC strain Alaskaâ„¢, and its "one-to-one" CBD/THC strain Midnightâ„¢. Tikun Olam's U.S. operations, established in 2015 as T.O. Global LLC, are a joint venture with Tikun Olam Ltd. (Israel). Tikun Olam also operates similar partnerships in Canada, Australia, United Kingdom and South Africa.
Visit www.tikunolamusa.com, and follow on Facebook, Twitter, and Instagram.
CONTACTS:
Tikun Olam Holding LLC/ Tikunâ„¢
Stephen Gardner
Chief Marketing Officer
sgardner@tikunolam.com
Media Relations
Tracey Henry / Brenda Loughery, Type A Media
Tracey@type-a-media.com; Brenda@type-a-media.com
Gia Moron, GVM Communications
GVM.Communications@yahoo.com
SOURCE Tikun Olam
Related Links
http://www.tikunolamusa.com
https://www.prnewswire.com/news-releases/israel-scientific-study-cannabis-safe-and-effective-for-regular-use-in-the-elderly-can-decrease-the-use-of-other-prescription-medicines-including-opioids-300600996.html
Hahaha!!! Watching North Korea leader walk across the border into south Korea was historic gives you hope in this world and hope for legalize marijuana all around the world! LOL
News Update
PAOG scoping locations on Mars for 3031
Hahaha... in all seriousness though, I want to hear about new clinics.
Go PAOG!!!
Super low float for the OTC. She has plenty of run left in her.
$PAOG
i think PAOG will be a great runner !
I have a good feeling for the next week! $PAOG
a lot of new eyes on this stock and with 4 more corporate owned clinics coming, we will see a new 52 week high. Just a matter of time...
Nice info. More upside in US than Canada as well. We could easily be a 150 Million market cap with steady growth.
In fact, a new report shows all 50 States will legalize marijuana by 2021
https://thefreshtoast.com/?p=36954
Even without recreational marijuana in Canada or California, North American legal marijuana sales soared 33% last year to $9.7 billion. ArcView expects that trend to continue at an annual rate of 28% through 2021 when there could be $25 billion or more in North American sales.
Bright future for $PAOG
Just a Reminder $PAOG appears to be entering a strong revenue growth phase... their financial statements state;
* $358,620 rev. generated in the 9 months ended Sept 2017
however,
* $187,390 rev. generated in the 3 months ended Sept 2017
This means the company just generated 52.3% of it's 9 months trailing revenue in just the last 3 months alone.
https://www.otcmarkets.com/financialReportViewer?symbol=PAOG&id=182972
... very strong revenue grow is starting to show up in the books... PR's detailing this strong rev. growth should be coming in the not too distant future.
ALso, with the roll-out of additional clincs on-deck, there could be a sustained revenue growth trend for sometime, ie: multiple quarters... I'm sure others have also figured this out considering the ramp-up in PAOG volume recently with no news.
So many different possibilities. Let you know.. Not every stock is a scam and not every CEO is a crook. Some stocks make it big. This could and will be one of them (IMO).
$PAOG We all know the drill, solid news and this will fly. Easy to beat these plays up but she is looking ready to me!
PAOG was showing so much POTENTIAL.
$PAOG good times are coming !
Good morning Vantilian!
Great article!!! I have a good feeling that's its gonna be HUGE .
GO PAOG $$$$$$
NOT a bad day at all for PAOG- entire MJ sector got hammered today, along with many stocks. if we get P.R. on MONDAY-we're off to the races again! just a matter of time for a strong rebound back up.
GO PAOG $$$$$
PAOG doesn't have to worry about any fighting with the FED's over recreational pot ... because POAG is only in medical pot... and medical pot has the full support of the President of the United States ...